Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : BIOTECH & TECHNOLOGY INVESTING *UNDERVALUED*{T/A F/A & V} -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (355)	6/1/2000 2:47:00 PM
From: joepcf	Respond to of 423

Thursday June 1, 8:33 am Eastern Time Company Press Release HIV-VAC, Inc. to Conduct AIDS Vaccine Trials TORONTO--(BUSINESS WIRE)--June 1, 2000--HIV-VAC, Inc, (OTC/BB: HIVC - news) has announced that the Company has received funding to begin the final stages of laboratory testing for its HIV/AIDS vaccine that could prove to be both a preventative and therapeutic agent. The trials will be conducted at the Russia Aids Centre and are expected to be completed within 9 to 12 months. Phase I and II human trials will commence once laboratory trials are completed. In a recent news conference, President Bill Clinton said that ``the development and the delivery of effective vaccines'' is the solution to rising AIDS, and other disease rates, worldwide. The Global AIDS Prevention Act of 2000, sponsored by Senators Barbara Boxer (D-Calif.) and Gordon Smith (R-Ore.), is a Congressional initiative that will authorize $2 billion in funding including Sen. John Kerry's (D-Mass.) White House Millennium Vaccine Initiative, a multi-million-dollar plan that features $1 billion in tax cuts for pharmaceutical companies, $900 million in funding for developing countries and a $50 million vaccine purchase fund. HIV-VAC's vaccine promises to not only prevent the disease, and also may prevent the onset of AIDS in HIV-positive patients. HIV-VAC, Inc. is developing the Skinner HIV-VAC AIDS vaccine which is based on a new and very unique approach to neutralizing the AIDS virus. Unlike many other AIDS vaccines under development, the Company believes that the Skinner vaccine has the potential to be effective with the AIDS virus' many mutant forms. This technology is based on a unique intracellular vaccine technology proven in clinical trials with herpes genitalis and pre-clinical research into cytomegalovirus and equine herpes vaccines. This has been under development by Dr. Skinner and his team for the past 10 years at the University of Birmingham, United Kingdom. The United Nations estimates that there are currently 33.6 million people infected worldwide with the AIDS virus. The disease is spreading at a rate of 10,000 people each day. It is estimated that the number of people infected with the AIDS virus by the end of the year 2000 will be 55 million. Sales of anti-HIV drugs increased to more than $3 billion last year and could reach $6 billion in coming years. The statements contained in this release which are not historical facts contain forward-looking information with respect to plans, projections or future performance of the company; the occurrence of which involves certain risks and uncertainties that could cause the company's actual results to differ materially from expected results. Such risks include the timing of implementation and the scope and success of the program described here. -------------------------------------------------------------------------------- Contact: HIV-VAC, Inc. Domenic Franco, 877/847-7719